These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 34268127)

  • 1. Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer.
    Daniello L; Elshiaty M; Bozorgmehr F; Kuon J; Kazdal D; Schindler H; Shah R; Volckmar AL; Lusky F; Diekmann L; Liersch S; Faehling M; Muley T; Kriegsmann M; Benesova K; Stenzinger A; Thomas M; Christopoulos P
    Front Oncol; 2021; 11():703893. PubMed ID: 34268127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
    Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
    JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Immune-Related Adverse Events and the Efficacy of Anti-PD-(L)1 Monotherapy in Non-Small Cell Lung Cancer: Adjusting for Immortal-Time Bias.
    Yu Y; Chen N; Yu S; Shen W; Zhai W; Li H; Fan Y
    Cancer Res Treat; 2024 Jul; 56(3):751-764. PubMed ID: 38186241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
    Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
    Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different associations between organ-specific immune-related adverse event and survival in non-small cell lung cancer patients treated with programmed death-1 inhibitors-based combination therapy.
    Chen Y; Shi Y; Ding H; Feng Y; Zhang T; Liang Y; Wang H; Song X; Chen B; Xia W; Mao Q; Shen B; Xu L; Dong G; Jiang F
    Ther Adv Med Oncol; 2023; 15():17588359231210678. PubMed ID: 38028145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between immune-related adverse events and the efficacy of PD-1 inhibitors in advanced esophageal cancer.
    Qin W; Yang L; Fan B; Zou B; Duan Y; Li B; Wang L
    Front Immunol; 2022; 13():931429. PubMed ID: 36248782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma.
    Ng KYY; Tan SH; Tan JJE; Tay DSH; Lee AWX; Ang AJS; Wong LWJ; Choo SP; Tai DW; Lee JJX
    Liver Cancer; 2022 Jan; 11(1):9-21. PubMed ID: 35222504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis.
    Bastacky ML; Wang H; Fortman D; Rahman Z; Mascara GP; Brenner T; Najjar YG; Luke JJ; Kirkwood JM; Zarour HM; Davar D
    Front Oncol; 2021; 11():749064. PubMed ID: 34900695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio for advanced non-small cell lung cancer patients with high PD-L1 tumor expression receiving pembrolizumab.
    Ksienski D; Wai ES; Alex D; Croteau NS; Freeman AT; Chan A; Patterson T; Clarkson M; Fiorino L; Poonja Z; Fenton D; Irons S; Lesperance M
    Transl Lung Cancer Res; 2021 Jan; 10(1):355-367. PubMed ID: 33569318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune-related adverse events of a PD-L1 inhibitor plus chemotherapy versus a PD-L1 inhibitor alone in first-line treatment for advanced non-small cell lung cancer: A meta-analysis of randomized control trials.
    Wang M; Liang H; Wang W; Zhao S; Cai X; Zhao Y; Li C; Cheng B; Xiong S; Li J; He J; Liang W
    Cancer; 2021 Mar; 127(5):777-786. PubMed ID: 33119182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-PD1-Induced Immune-Related Adverse Events and Survival Outcomes in Advanced Melanoma.
    Suo A; Chan Y; Beaulieu C; Kong S; Cheung WY; Monzon JG; Smylie M; Walker J; Morris D; Cheng T
    Oncologist; 2020 May; 25(5):438-446. PubMed ID: 32048768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer.
    Simonaggio A; Michot JM; Voisin AL; Le Pavec J; Collins M; Lallart A; Cengizalp G; Vozy A; Laparra A; Varga A; Hollebecque A; Champiat S; Marabelle A; Massard C; Lambotte O
    JAMA Oncol; 2019 Sep; 5(9):1310-1317. PubMed ID: 31169866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune-Related Adverse Event-Related Adrenal Insufficiency Mediates Immune Checkpoint Inhibitors Efficacy in Cancer Treatment.
    Zhang S; Wu J; Zhao Y; Zhang J; Zhang X; Wu C; Zhang Z; Guo Z
    Cancer Manag Res; 2024; 16():151-161. PubMed ID: 38501053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer Needing Treatment Interruption Because of Adverse Events: A Retrospective Multicenter Analysis.
    Ksienski D; Wai ES; Croteau N; Fiorino L; Brooks E; Poonja Z; Fenton D; Geller G; Glick D; Lesperance M
    Clin Lung Cancer; 2019 Jan; 20(1):e97-e106. PubMed ID: 30337270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncologic Outcome and Immune Responses of Radiotherapy with Anti-PD-1 Treatment for Brain Metastases Regarding Timing and Benefiting Subgroups.
    Trommer M; Adams A; Celik E; Fan J; Funken D; Herter JM; Linde P; Morgenthaler J; Wegen S; Mauch C; Franklin C; Galldiks N; Werner JM; Kocher M; Rueß D; Ruge M; Meißner AK; Baues C; Marnitz S
    Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between Programmed Cell Death Protein Ligand 1 Expression and Immune-related Adverse Events in Non-small-cell Lung Cancer Patients Treated with Pembrolizumab.
    Sugisaka J; Toi Y; Taguri M; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Ono H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y; Sugawara S
    JMA J; 2020 Jan; 3(1):58-66. PubMed ID: 33324776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
    Ricciuti B; Genova C; De Giglio A; Bassanelli M; Dal Bello MG; Metro G; Brambilla M; Baglivo S; Grossi F; Chiari R
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):479-485. PubMed ID: 30506406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune-Related Adverse Events and Their Association With the Effectiveness of PD-1/PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Real-World Study From China.
    Chen X; Nie J; Dai L; Hu W; Zhang J; Han J; Ma X; Tian G; Han S; Wu D; Wang Y; Long J; Zhang Z; Fang J
    Front Oncol; 2021; 11():607531. PubMed ID: 33747922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases.
    Zhang M; Rodrigues AJ; Pollom EL; Gibbs IC; Soltys SG; Hancock SL; Neal JW; Padda SK; Ramchandran KJ; Wakelee HA; Chang SD; Lim M; Hayden Gephart M; Li G
    J Neurooncol; 2021 Mar; 152(1):125-134. PubMed ID: 33415659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy.
    Das S; Ciombor KK; Haraldsdottir S; Pumpalova Y; Sahin IH; Pineda G; Shyr Y; Lin EP; Hsu CY; Chu SK; Goff LW; Cardin DB; Bilen MA; Fisher GA; Wu C; Berlin J
    Oncologist; 2020 Aug; 25(8):669-679. PubMed ID: 31943525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.